Olink Holding AB (publ) (OLK) is a renowned Swedish life sciences company that specializes in the development and distribution of protein biomarker discovery tools for precision medicine, scientific research, and drug development. The company is committed to advancing precision medicine and healthcare by providing a robust and innovative biomarker discovery platform for translational scientists and clinicians.
Established in 2004, Olink has carved a niche for itself in the biotechnology industry. It operates through a science-driven approach that leverages high-quality tools for the identification and validation of novel protein biomarkers. The company's proprietary Proximity Extension Assay (PEA) technology has revolutionized protein biomarker discovery by offering a high degree of specificity and sensitivity. This in turn helps translational scientists in the efficient evaluation of potential protein biomarkers to identify the ones with the most promising diagnostic or therapeutic potential.
Olink's PEA technology has been hailed for delivering scalability and reproducibility. It allows researchers to interrogate numerous proteins simultaneously, ensures the delivery of high-quality data from minimal sample volumes, and enables efficient and cost-effective studies using large sample numbers. Notably, this is coupled with an expansive and ever-growing protein biomarker catalogue that covers multiple areas of disease understanding and therapeutic development.
Furthermore, the company has also built a substantial biobank network that includes various sample types, over multiple disease areas, underscoring its comprehensive approach to biomarker discovery. This helps in bridging the translational science gap, facilitating biomarker discovery and validation, and accelerating the drug development process.
Globally, Olink is recognized for its commitment to quality, innovation, and collaboration. It has established collaborations with academic and industrial organizations worldwide, enriching the global scientific community with its innovative solutions.
Ranked among the biotechnology industry's trailblazers, Olink's commitment to enhancing precision medicine and healthcare through its advanced biomarker discovery platform remains unwavering. By constantly pushing the boundaries of protein biomarker discovery, the company is paving the way for a better understanding of human biology and disease. In doing so, Olink continues to contribute to the transformation of precision medicine and healthcare, positioning itself as a leader in the biotech industry.